Is Moderna Winning on Vaccine Efficacy?
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) hold the top spots in the coronavirus vaccine market. Both won authorization last December. Both have won orders for 500 million doses from the U.S. government. And together, they've fully vaccinated the biggest share of Americans -- 98 million by Pfizer and 67 million by Moderna. That compares to 14 million by smaller player Johnson & Johnson.
When it comes to efficacy, J&J lagged behind the leaders from the start. It reported efficacy of 85% against severe disease in clinical trials. That compares to more than 95% for Moderna and Pfizer. These makers of mRNA vaccines seem about equal. Now, though, new studies are showing us more data. One in particular suggests Moderna may be the best at keeping people out of the hospital. Does this mean Moderna's vaccine is better than Pfizer's? Let's take a closer look.
Source Fool.com